Schetelig, Johannes http://orcid.org/0000-0002-2780-2981
Chevallier, Patrice
van Gelder, Michel
Hoek, Jennifer
Hermine, Olivier
Chakraverty, Ronjon
Browne, Paul
Milpied, Noel
Malagola, Michele
Socié, Gerard
Delgado, Julio
Deconinck, Eric
Damaj, Ghandi
Maury, Sebastian
Beelen, Dietrich
Quoc, Stéphanie Nguyen
Shankara, Paneesha
Brecht, Arne
Mayer, Jiri
Hunault-Berger, Mathilde http://orcid.org/0000-0001-7777-5216
Bittenbring, Jörg
Thieblemont, Catherine
Lepretre, Stéphane
Baldauf, Henning
de Wreede, Liesbeth C.
Tournilhac, Olivier
Yakoub-Agha, Ibrahim
Kröger, Nicolaus http://orcid.org/0000-0002-2961-4183
Dreger, Peter http://orcid.org/0000-0002-7429-8570
Article History
Received: 25 March 2020
Revised: 15 September 2020
Accepted: 18 September 2020
First Online: 2 October 2020
Change Date: 12 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-021-01516-2
Compliance with ethical standards
:
: JS—consultancy honoraria from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Molmed; lecturer fees from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Novartis; research support from Genzyme, Sanofi, GSK, Novartis, Abbvie. OH—consultancy honoraria from AB Science; research support from AB Science, Celgene, Alexion, and Inatherys. DG—consultancy honoraria from Roche, Takeda, Iqone; lecturer fees from Abbvie, Celgene, Sanofi-Genzyme; research support from Takeda. NK—lecturer fees from Neovii, Sanofi, Novartis, Kiadis, Celgene, Amgen, Riemser, Chugai, Janssen; research support from Novartis, Celgene, Riemser, Neovii. PD—consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. The remaining authors declared no conflict of interest.